FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310235081> ?p ?o ?g. }

• W4310235081 abstract "Abstract Background Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant tumor characterized by an intensive desmoplastic reaction due to the exaggerated presence of the extracellular (ECM) matrix components. Liver fibroblasts close to the tumor, activated by transforming growth factor (TGF)-β1 and expressing high levels of α-smooth muscle actin (α-SMA), become cancer-associated fibroblasts (CAFs). CAFs are deputed to produce and secrete ECM components and crosstalk with cancer cells favoring tumor progression and resistance to therapy. Overexpression of Notch signaling is implicated in CCA development and growth. The study aimed to determine the effectiveness of the Notch inhibitor, Crenigacestat, on the surrounding microenvironment of iCCA. Methods We investigated Crenigacestat’s effectiveness in a PDX model of iCCA and human primary culture of CAFs isolated from patients with iCCA. Results In silico analysis of transcriptomic profiling from PDX iCCA tissues treated with Crenigacestat highlighted “liver fibrosis” as one of the most modulated pathways. In the iCCA PDX model, Crenigacestat treatment significantly ( p < 0.001) reduced peritumoral liver fibrosis. Similar results were obtained in a hydrodynamic model of iCCA. Bioinformatic prediction of the upstream regulators related to liver fibrosis in the iCCA PDX treated with Crenigacestat revealed the involvement of the TGF-β1 pathway as a master regulator gene showing a robust connection between TGF-β1 and Notch pathways. Consistently, drug treatment significantly ( p < 0.05) reduced TGF-β1 mRNA and protein levels in tumoral tissue. In PDX tissues, Crenigacestat remarkably inhibited TGF-β signaling and extracellular matrix protein gene expression and reduced α-SMA expression. Furthermore, Crenigacestat synergistically increased Gemcitabine effectiveness in the iCCA PDX model. In 31 iCCA patients, TGF-β1 and α-SMA were upregulated in the tumoral compared with peritumoral tissues. In freshly isolated CAFs from patients with iCCA, Crenigacestat significantly ( p < 0.001) inhibited Notch signaling, TGF-β1 secretion, and Smad-2 activation. Consequently, Crenigacestat also inactivated CAFs reducing ( p < 0.001) α-SMA expression. Finally, CAFs treated with Crenigacestat produced less ( p < 005) ECM components such as fibronectin, collagen 1A1, and collagen 1A2. Conclusions Notch signaling inhibition reduces the peritumoral desmoplastic reaction in iCCA, blocking the TGF-β1 canonical pathway." @default.
• W4310235081 created "2022-11-30" @default.
• W4310235081 creator A5006550872 @default.
• W4310235081 creator A5014212595 @default.
• W4310235081 creator A5014448575 @default.
• W4310235081 creator A5016695149 @default.
• W4310235081 creator A5028462736 @default.
• W4310235081 creator A5040373155 @default.
• W4310235081 creator A5044205409 @default.
• W4310235081 creator A5075457339 @default.
• W4310235081 creator A5076607243 @default.
• W4310235081 creator A5079077713 @default.
• W4310235081 creator A5091038323 @default.
• W4310235081 date "2022-11-28" @default.
• W4310235081 modified "2023-10-18" @default.
• W4310235081 title "Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition" @default.
• W4310235081 cites W1493825968 @default.
• W4310235081 cites W1899897445 @default.
• W4310235081 cites W1966731849 @default.
• W4310235081 cites W1983696189 @default.
• W4310235081 cites W1987062221 @default.
• W4310235081 cites W2013256879 @default.
• W4310235081 cites W2034584820 @default.
• W4310235081 cites W2038350469 @default.
• W4310235081 cites W2052364863 @default.
• W4310235081 cites W2057079071 @default.
• W4310235081 cites W2059070178 @default.
• W4310235081 cites W2062809449 @default.
• W4310235081 cites W2066967801 @default.
• W4310235081 cites W2067896088 @default.
• W4310235081 cites W2071416644 @default.
• W4310235081 cites W2073047578 @default.
• W4310235081 cites W2080662048 @default.
• W4310235081 cites W2087106096 @default.
• W4310235081 cites W2091411431 @default.
• W4310235081 cites W2101004105 @default.
• W4310235081 cites W2103805056 @default.
• W4310235081 cites W2105924284 @default.
• W4310235081 cites W2109001750 @default.
• W4310235081 cites W2110502585 @default.
• W4310235081 cites W2141872434 @default.
• W4310235081 cites W2178003817 @default.
• W4310235081 cites W2256103742 @default.
• W4310235081 cites W2322915906 @default.
• W4310235081 cites W2524927879 @default.
• W4310235081 cites W2530953922 @default.
• W4310235081 cites W2559759417 @default.
• W4310235081 cites W2727544707 @default.
• W4310235081 cites W2767217200 @default.
• W4310235081 cites W2789927805 @default.
• W4310235081 cites W2802519389 @default.
• W4310235081 cites W2889027967 @default.
• W4310235081 cites W2891525728 @default.
• W4310235081 cites W2911671599 @default.
• W4310235081 cites W2920849174 @default.
• W4310235081 cites W2932470287 @default.
• W4310235081 cites W2933143705 @default.
• W4310235081 cites W2942656542 @default.
• W4310235081 cites W2973596517 @default.
• W4310235081 cites W2974661394 @default.
• W4310235081 cites W2979697899 @default.
• W4310235081 cites W2980085376 @default.
• W4310235081 cites W2981306335 @default.
• W4310235081 cites W3004896727 @default.
• W4310235081 cites W3027267262 @default.
• W4310235081 cites W3039360174 @default.
• W4310235081 cites W3099557316 @default.
• W4310235081 cites W3111278897 @default.
• W4310235081 cites W3136684164 @default.
• W4310235081 cites W3181934357 @default.
• W4310235081 cites W3193119799 @default.
• W4310235081 cites W3207337024 @default.
• W4310235081 cites W3217416647 @default.
• W4310235081 cites W4206231335 @default.
• W4310235081 cites W4220860695 @default.
• W4310235081 cites W4223426049 @default.
• W4310235081 cites W4225774208 @default.
• W4310235081 cites W4281559521 @default.
• W4310235081 doi "https://doi.org/10.1186/s13046-022-02536-6" @default.
• W4310235081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36443822" @default.
• W4310235081 hasPublicationYear "2022" @default.
• W4310235081 type Work @default.
• W4310235081 citedByCount "2" @default.
• W4310235081 countsByYear W43102350812023 @default.
• W4310235081 crossrefType "journal-article" @default.
• W4310235081 hasAuthorship W4310235081A5006550872 @default.
• W4310235081 hasAuthorship W4310235081A5014212595 @default.
• W4310235081 hasAuthorship W4310235081A5014448575 @default.
• W4310235081 hasAuthorship W4310235081A5016695149 @default.
• W4310235081 hasAuthorship W4310235081A5028462736 @default.
• W4310235081 hasAuthorship W4310235081A5040373155 @default.
• W4310235081 hasAuthorship W4310235081A5044205409 @default.
• W4310235081 hasAuthorship W4310235081A5075457339 @default.
• W4310235081 hasAuthorship W4310235081A5076607243 @default.
• W4310235081 hasAuthorship W4310235081A5079077713 @default.
• W4310235081 hasAuthorship W4310235081A5091038323 @default.
• W4310235081 hasBestOaLocation W43102350811 @default.
• W4310235081 hasConcept C118131993 @default.
• W4310235081 hasConcept C121608353 @default.
• W4310235081 hasConcept C126322002 @default.

• next